Team Prothea Anne

Anne Moore

Chief Operating & Finance Officer

linkedin

Anne has PhDs in Signal Processing and Molecular Biology. Prior to Prothea she worked as a programme manager for BAE Systems, and then at the University of Edinburgh, where she managed a portfolio of translational healthcare projects.

Annya Bruce

Head of Clinical Affairs

linkedin

Annya has a PhD in Molecular Imaging and is Head of Clinical Operations at Prothea Technologies. Annya has a background in clinical trial design and delivery, regulatory frameworks and compliance, data management systems and ensuring on-time and on-budget study outcomes. At Prothea, Annya leads the strategic design and execution of clinical validation programmes focused on lung disease, generating high-quality, endpoint-driven evidence to support regulatory approval and clinical adoption.

Team Prothea Caitlin

Caitlin Toogood

Medical Production Engineer

linkedin

Caitlin qualified with a BEng(Hons) in Mechanical Engineering from Curtin University, Perth, Australia; and a MSc in Biomedical Engineering from the Technische Hochschule and University of Lübeck. With subsequent experience in medical device development and biotech manufacturing, Caitlin specializes at Prothea in manufacturing scale-up and process development.

Team Prothea Charlotte

Charlotte Parry

Head of Fibre Engineering

linkedin

Charlotte has a background in physics, with PhD in quantum optics. As head of fibre engineering she is responsible for the transfer of technology from research and development through to manufacturing.

Team Prothea Crispin

Crispin Simon

Executive Chair

linkedin

Crispin was Smith & Nephew’s Group Strategy Director and President of its Endoscopy Division in the US; and then led the team that delivered $400m of exits at Biocompatibles plc. Prior to Prothea, Crispin served as the UK Trade Commissioner for South Asia, based in Mumbai, India.

Team Prothea Fabian

Fabian Klarner

VP Engineering, Manging Director Prothea Technologies GmbH

linkedin

Fabian has a PhD in Accelerator Physics and more than 10 years in the medical technology industry – latterly leading proton therapy R&D at Varian. Fabian leads Prothea’s Manufacturing activities from the Cologne site.

Team Prothea Gareth

Gareth Williams

VP Systems Research and Development

linkedin

Gareth is Vice President of research and development at Prothea. He is a specialist in optical instrumentation with a PhD in chemical physics and a background of producing novel optical sensing and imaging instrumentation. He is leading Prothea’s research and development for their next generation fluorescence imaging and treatment platforms.

Team Prothea Harry

Harry Wood

Head of Fibre

linkedin

Harry is head of fine tool research and development at Prothea. He has a PhD in the physics of optical waveguides for medicine and 7 years experience designing minimally invasive diagnostic and therapeutic tools.

Team Prothea Hazel

Hazel Stewart

Head of Systems Engineering

linkedin

Hazel has a PhD in Optical Medical Imaging and has several years’ experience utilising fluorescence lifetime for various applications, including studying differences between healthy and cancerous cells and building fluorescence lifetime imaging systems. Hazel leads on the testing and technical documentation for various medical devices for Prothea.

Team Prothea Hilola

Hilola Hakimova

Quality Manager

linkedin

Hilola has an MSc in Neuroscience and a BSc in Bio & Brain Engineering and has held quality and regulatory posts at Class III and IIb medical device manufacturers, guiding certifications across Europe and Asia.  Hilola steers our product‑lifecycle processes, aligning manufacturing readiness and regulatory strategy.

Team Prothea Jim

Jim Stone

Chief Technical Officer

linkedin

Jim is the Chief Technical Officer. He has a research background leading the development of new optical fibres for use in medical technology. He has run research programmes in academia and industry. His role is to have technical oversight of the project.

Team Prothea Joel

Joel Collins

Head of Software

linkedin

Joel is Head of Software. He has a PhD in physics and a background in developing software for data acquisition systems and medical data processing. His role is to develop the core data acquisition software and its integration with real-time AI-driven data analysis.

Professor Kev Dhaliwal

Chief Medical and Chief Scientific Officer

linkedin

Chair of Molecular Imaging & Healthcare Technology and Consultant Physician in Respiratory Medicine at the University of Edinburgh, Scotland, UK. Kev’s academic group investigates disruptive technologies to advance Respiratory Medicine and Critical Care. Kev is a Director of Prothea Technologies and Chief Scientific and Medical Officer.

Mazi Zarrehparvar

SVP Prothea Technologies US & Head of Business Development

linkedin

Mazi brings more than 35 years of business experience with a background in investment banking and recent leadership roles in two other deep-tech spinoffs.  Mazi earned his BA from UC Berkeley, and holds an MBA and MSc from the Universities of Chicago and Oxford respectively.   Mazi is based in the Bay area and leads Prothea’s activities in the US.

Morag Frazer

Business Support Officer

Morag’s background is in Operations & Office Management as well as Intranet Design, Content Management and Print Production Management. At Prothea Technologies Morag provides Executive Support to the COO and CEO, Business Development, Marketing, Office Management, Conference Planning and Business Operations.

Team Prothea Qiang

Qiang Wang

Head of Artificial Intelligence R&D

linkedin

Qiang holds a PhD from the University of Leeds (2017) in signal and image processing for electrical tomography and then moved to biomedical imaging at the University of Edinburgh (2018). With over 15 years of experience in signal and image processing and software engineering, he brings deep technical expertise to developing innovative healthcare technologies.

Vikki Young

VP Regulatory & Quality Affairs

Vikki is head of regulatory and quality affairs. She has a background in clinical trials and establishing Quality Management Systems. This role is to ensure that the project is carried out within the framework of medical device regulation and that the algorithms and associated software are developed and documented with appropriate consideration of design control, traceability and risk assessment.

Team Prothea Ahsan

Ahsan Akram

Clinical Advisory Panel

linkedin

Ahsan Akram is  a Clinician Scientist and Fellow at the University of Edinburgh and Honorary Consultant in Respiratory Medicine in NHS Lothian.  Having completed a PhD in Optical Imaging, he conducted research in stromal biology in NSCLC supported by Cancer Research UK.  Now under Ahsan’s UKRI fellowship, his group researches the tumour microenvironment to understand how different cells shape tumour progression and patient outcome. Ahsan is a consultant to the Company.

Charles (Chuck) Carignan MD

Non-Executive Director

linkedin

Dr. Charles S. Carignan is the Executive Chairman of Cairdac and of Samantree Medical and a Director of Biothea and Neurofenix. Previous roles included founder President and CEO of NinePoint Medical, Executive Vice President and Chief Medical Officer of Novasys Medical, Inc. (sold to Roper), Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus (sold to Bayer). Chuck is Chair of the Clinical and Regulatory Committee.

John Yianni

Non-Executive Director

linkedin

John is a partner at Earlybird Health which he joined as a Partner in 2016 and has over 30 years of experience in the medical device industry. He has founded several successful startups, including Biocompatibles, Thermocore Medical, Securus Medical Group, Reverse Medical, and CryoTherapeutics, where he serves as CEO. John holds a doctorate in Biophysics from the University of Salford in the UK and completed postdoctoral research at both the University of Salford and the University of California, Los Angeles (UCLA). John is Chair of the Remuneration Committee.

Peter Stratford

Non-Executive Director

linkedin

Commercially focussed leader with medical device, pharma and combination products experience across all major geographies, Peter was a Director of Biocompatibles plc prior to the acquisition by BTG plc where he served as CTO prior to its acquisition by Boston Scientifc. Author and inventor across numerous healthcare areas including cardiovascular, ophthalmology and oncology. Peter is Chair of the Intellectual Property Committee.

Thomas Raueiser, PhD

Non-Executive Director

linkedin

Thomas is Deputy Head of NRW Bank’s Life Sciences & Cleantech team and authorised signatory (Prokurist) of Gründerfonds Ruhr.  He has more than 15 years of investment experience in the venture capital industry.  He has accompanied numerous investments to a successful exit and was appointed to the advisory boards of various portfolio companies.  Before joining NRW Bank, he worked for Deutsche Bank AG and Credit Suisse First Boston in corporate investment banking and private wealth management. Thomas is Chair of the Audit Committee.

Yoann Bonnamour

Non-Executive Director

linkedin

Yoann Bonnamour joined Mérieux Equity Partners in May 2020 having started his career as Equity Capital Market analyst at Bryan Garnier, focusing on Biotech, Diagnostics and Medical Devices companies. Yoann then joined M Capital Partners in 2014, setting up the Lyon office in 2015. He has been a board member of many successful healthcare companies.  Yoann graduated from University of Pharmacy of Montpellier and holds a Master Degree from EM Lyon Business School.

To top